Leap therapeutics to present preclinical data of fl-501, a novel gdf-15 neutralizing antibody, at the aacr 2025 annual meeting

Fl-501 fully restored body composition and reversed key indicators of cachexia in preclinical models findings confirm gdf-15's role in cachexia and support advancing fl-501 into the clinic cambridge, mass. , april 25, 2025 /prnewswire/ -- leap therapeutics, inc. (nasdaq:lptx), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced it will present preclinical data of fl-501 in a poster presentation at the american association for cancer research (aacr) annual meeting taking place april 25-30 in chicago, illinois.
LPTX Ratings Summary
LPTX Quant Ranking